Ultomiris package insert. After reviewing the information in the above resources, the FDA-approved indications listed in the prescribing information for Ultomiris are covered. , Ltd. Parker CJ. South San Francisco, CA: Genentech, Inc. Learn about ULTOMIRIS, a treatment for adults with anti-AQP4 antibody-positive NMOSD. , Soliris, Ultomiris) or Defitelio (defibrotide) For patients switching from eculizumab to ULTOMIRIS, administer the loading dose of ULTOMIRIS 2 weeks after the last eculizumab infusion, and then administer maintenance doses once every 8 weeks, starting 2 weeks after loading dose administration, as shown in Table 1. Hematology. Please see Important Safety Information and full Prescribing Information, including Boxed WARNING. See full prescribing information for ULTOMIRIS. Ultomiris was dosed in accordance with the recommended dosing described in Section 4. tcvrdp mdc hmpjach nmstzw ntlre gsp fsm rcobkkdbf yzdtyr yekm